Liprolog Mix50 Kwikpen (Insulin Lispro)

Insulin lispro binds to insulin receptors on muscle and fat cells, triggering a cascade that increases glucose uptake, promotes glycogen synthesis, and suppresses hepatic glucose production. This rapid action lowers blood glucose shortly after injection, mimicking the body’s natural insulin response to meals.

The dose of Liprolog Mix50 Kwikpen is individualized. A qualified prescriber determines the amount based on the patient’s blood‑glucose monitoring, carbohydrate intake, and overall diabetes management plan. Patients should follow the dosing instructions provided by their healthcare professional.

Data on insulin lispro use in pregnancy and lactation are limited. It may be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should assess each case and monitor glucose closely.

To order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and necessary import documentation.

Liprolog Mix50 Kwikpen delivers insulin lispro, which has a faster onset and shorter duration than regular human insulin, similar to other rapid‑acting analogues such as insulin aspart or glulisine. Its prefilled pen format offers convenient dosing and accurate delivery compared with vial‑and‑syringe methods.

Store the Kwikpen at 2‑8 °C (refrigerated) and protect it from light. Do not freeze or shake the pen. Once in use, it may be kept at controlled room temperature (up to 30 °C) for a maximum of 28 days, as indicated on the label.

The product is a prefilled Kwikpen designed for subcutaneous injection. After selecting the prescribed dose, the user inserts a new needle, primes the pen, and injects into the abdomen, thigh, or upper arm at a 90° angle. Dispose of used needles safely.

The most serious risks include severe hypoglycaemia, which can cause loss of consciousness, and allergic reactions such as anaphylaxis. Rarely, patients may develop diabetic ketoacidosis if insulin therapy is abruptly discontinued. Prompt medical attention is required if any of these events occur.

Individuals with a known hypersensitivity to insulin lispro or any excipients in the pen should avoid its use. It is also contraindicated in patients experiencing hypoglycaemia unawareness or those who cannot reliably monitor glucose levels. Clinicians must evaluate each patient’s suitability before prescribing.